MDT

95.38

-0.51%↓

VEEV

285.28

-0.56%↓

145.7

+1.8%↑

HQY

93.16

-0.2%↓

TLRY

1.5

-3.85%↓

MDT

95.38

-0.51%↓

VEEV

285.28

-0.56%↓

145.7

+1.8%↑

HQY

93.16

-0.2%↓

TLRY

1.5

-3.85%↓

MDT

95.38

-0.51%↓

VEEV

285.28

-0.56%↓

145.7

+1.8%↑

HQY

93.16

-0.2%↓

TLRY

1.5

-3.85%↓

MDT

95.38

-0.51%↓

VEEV

285.28

-0.56%↓

145.7

+1.8%↑

HQY

93.16

-0.2%↓

TLRY

1.5

-3.85%↓

MDT

95.38

-0.51%↓

VEEV

285.28

-0.56%↓

145.7

+1.8%↑

HQY

93.16

-0.2%↓

TLRY

1.5

-3.85%↓

Home・Aktien・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

110.38 2.09

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

108.12

Max

113.25

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.9M -47M
Verkäufe	16M 49M
Gewinnspanne	-96.144
Angestellte	283
EBITDA	6.9M -40M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+8.36% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	738M 6.7B
Vorheriger Eröffnungskurs	108.29
Vorheriger Schlusskurs	110.38

Nachrichtenstimmung

By Acuity

40%

60%

123 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

60 / 65.58 Unterstützung & Widerstand

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Okt. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20. Okt. 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Okt. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20. Okt. 2025, 22:14 UTC

Market Talk

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20. Okt. 2025, 22:00 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20. Okt. 2025, 21:49 UTC

Akquisitionen, Fusionen, Übernahmen

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20. Okt. 2025, 20:56 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20. Okt. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Okt. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

20. Okt. 2025, 20:38 UTC

Ergebnisse

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20. Okt. 2025, 20:38 UTC

Ergebnisse

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20. Okt. 2025, 20:38 UTC

Ergebnisse

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20. Okt. 2025, 20:36 UTC

Ergebnisse

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20. Okt. 2025, 20:36 UTC

Ergebnisse

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20. Okt. 2025, 20:36 UTC

Ergebnisse

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20. Okt. 2025, 20:36 UTC

Ergebnisse

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20. Okt. 2025, 20:16 UTC

Market Talk

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20. Okt. 2025, 20:05 UTC

Ergebnisse

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20. Okt. 2025, 19:39 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20. Okt. 2025, 19:34 UTC

Market Talk

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20. Okt. 2025, 19:32 UTC

Market Talk

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20. Okt. 2025, 19:00 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20. Okt. 2025, 18:29 UTC

Market Talk

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20. Okt. 2025, 18:11 UTC

Market Talk

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20. Okt. 2025, 18:04 UTC

Market Talk

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20. Okt. 2025, 17:03 UTC

Market Talk

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20. Okt. 2025, 17:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Okt. 2025, 17:01 UTC

Market Talk

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20. Okt. 2025, 16:43 UTC

Market Talk

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20. Okt. 2025, 16:25 UTC

Market Talk

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

8.36% Vorteil

12-Monats-Prognose

Durchschnitt 119.5 USD 8.36%

Hoch 142 USD

Tief 95 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Stimmung

By Acuity

123 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.